User profiles for Friedrich Stölzel
 | Friedrich StölzelUniversity Hospital Schleswig-Holstein Verified email at uksh.de Cited by 6274 |
Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey
…, R Marks, M Lübbert, R Wäsch, C Scheid, F Stölzel… - Leukemia, 2015 - nature.com
Despite major improvements in allogeneic hematopoietic cell transplantation over the past
decades, corticosteroid-refractory (SR) acute (a) and chronic (c) graft-versus-host disease (…
decades, corticosteroid-refractory (SR) acute (a) and chronic (c) graft-versus-host disease (…
[HTML][HTML] New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management
Pharmacological and cellular treatment of cancer is changing dramatically with benefits for
patient outcome and comfort, but also with new toxicity profiles. The majority of adverse …
patient outcome and comfort, but also with new toxicity profiles. The majority of adverse …
[PDF][PDF] Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of …
…, HJ Tischler, R Stuhlmann, U Schuler, F Stölzel… - Journal of clinical …, 2011 - Citeseer
Purpose The current European LeukemiaNet (ELN) recommendations for acute myeloid
leukemia (AML) propose a new risk reporting system, integrating molecular and cytogenetic …
leukemia (AML) propose a new risk reporting system, integrating molecular and cytogenetic …
Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid …
…, C Groth, A Schubert, M Mende, F Stölzel… - The Lancet …, 2018 - thelancet.com
Background Monitoring of measurable residual disease (MRD) in patients with advanced
myelodysplastic syndromes (MDS) or acute myeloid leukaemia (AML) who achieve a …
myelodysplastic syndromes (MDS) or acute myeloid leukaemia (AML) who achieve a …
Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells
…, U Holtick, C Scheid, A Spyridonidis, F Stölzel… - Nature medicine, 2018 - nature.com
Individuals with acute myeloid leukemia (AML) harboring an internal tandem duplication (ITD)
in the gene encoding Fms-related tyrosine kinase 3 (FLT3) who relapse after allogeneic …
in the gene encoding Fms-related tyrosine kinase 3 (FLT3) who relapse after allogeneic …
A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial
…, B Mohr, U Oelschlaegel, F Stölzel… - Blood, The Journal …, 2010 - ashpublications.org
We present an analysis of prognostic factors derived from a trial in patients with acute myeloid
leukemia older than 60 years. The AML96 trial included 909 patients with a median age of …
leukemia older than 60 years. The AML96 trial included 909 patients with a median age of …
Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia
In acute myeloid leukemia (AML), therapy resistance frequently occurs, leading to high
mortality among patients. However, the mechanisms that render leukemic cells drug resistant …
mortality among patients. However, the mechanisms that render leukemic cells drug resistant …
CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome
…, M Kaufmann, S Herold, F Stölzel… - Blood, The Journal …, 2022 - ashpublications.org
Biallelic mutations of the CEBPA gene (CEBPA bi ) define a distinct entity associated with
favorable prognosis; however, the role of monoallelic mutations (CEBPA sm ) is poorly …
favorable prognosis; however, the role of monoallelic mutations (CEBPA sm ) is poorly …
TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML
…, K Sweet, H Altmann, GA Foulds, F Stölzel… - Blood …, 2020 - ashpublications.org
Somatic TP53 mutations and 17p deletions with genomic loss of TP53 occur in 37% to 46%
of acute myeloid leukemia (AML) with adverse-risk cytogenetics and correlate with primary …
of acute myeloid leukemia (AML) with adverse-risk cytogenetics and correlate with primary …
[HTML][HTML] Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT
…, CJM Halkes, JHF Falkenburg, F Stölzel… - Nature …, 2019 - nature.com
The major cause of death after allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
for acute myeloid leukemia (AML) is disease relapse. We investigated the expression of …
for acute myeloid leukemia (AML) is disease relapse. We investigated the expression of …